DCPIB NEW
| Price | $55 | $94 | $196 |
| Package | 5mg | 10mg | 25mg |
| Min. Order: | |
| Supply Ability: | 10g |
| Update Time: | 2025-12-22 |
Product Details
| Product Name: DCPIB | CAS No.: 82749-70-0 |
| Purity: 99.87% | Supply Ability: 10g |
| Release date: 2025/12/22 |
Product Introduction
Bioactivity
| Name | DCPIB |
| Description | DCPIB, a known specific and potent inhibitor of volume-regulated anion channels (VRAC),DCPIB displayed superior selectivity toward TRESK with an IC50 of 0.14 μM, demonstrating at least 100-fold higher affinity over TREK1/TRAAK channels. |
| In vitro | DCPIB, a known specific and potent inhibitor of volume-regulated anion channels (VRAC), has been reported to activate TREK1 and TREK2 in astrocytes and in vitro recently.?In the present study, we demonstrated DCPIB also voltage dependently activated TRAAK besides TREK1/TREK2, showing DCPIB activated all TREK subfamily members.?In contrast, the compound potently inhibited several other K2P channels with no voltage dependence, including TRESK, TASK1, and TASK3.?DCPIB displayed superior selectivity toward TRESK with an IC50 of 0.14 μM, demonstrating at least 100-fold higher affinity over TREK1/TRAAK channels.?Furthermore, the impaired ion selectivity filter region greatly impaired the activating effect of DCPIB on TREK1 but not the inhibitory effect of DCPIB on TRESK.?This indicates distinct molecular determinants underlying the effect of DCPIB on TREK1 or TRESK channels.?DCPIB played diverse effects on K2P channels and could be a useful tool for further investigating structure-function studies of K2P channels. |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Solubility Information | DMSO : 250 mg/mL (584.99 mM), Sonication is recommended. 10% DMSO+40% PEG300+5% Tween 80+45% Saline : 4 mg/mL (9.36 mM), Sonication is recommended. |
| Keywords | VRAC | TRESK | TASK-3 | TASK-1 | swelling | rMCAO | PotassiumChannel | Potassium Channel | KcsA | ischemia | Inhibitor | inhibit | DCPIB | CPAE cell | COS-7 | Cl-Channels | Chloridechannel | Chloride channel | Chloride Channel | cardiomyocytes |
| Inhibitors Related | Minoxidil sulfate | Tannic acid | Urethane | Hydrochlorothiazide | Tetraethylammonium bromide | Halothane | Butamben | Ursodeoxycholic acid | Cloperastine hydrochloride | Fenamic acid | Nifedipine | Indapamide |
| Related Compound Libraries | Bioactive Compound Library | Pain-Related Compound Library | Membrane Protein-targeted Compound Library | Inhibitor Library | NO PAINS Compound Library | Bioactive Compounds Library Max | Potassium Channel Targeted Library | Covalent Inhibitor Library | Ion Channel Targeted Library | Anti-Cancer Compound Library |
Company Profile Introduction
Target Molecule Corp. (TargetMol) is a global high-tech enterprise, headquartered in Boston, MA, specializing in chemical and biological research product and service to meet the research needs of global customers.
TargetMol has evolved into one of the biggest global compound library and small molecule suppliers and a customer based on 40+ countries. TargetMol offers over 80 types of compound libraries and a wide range of high-quality research chemicals including inhibitors, activator, natural compounds, peptides, inhibitory antibodies, and novel life-science kits, for laboratory and scientific use. Besides, virtual screening service is also available for customers who would like to conduct the computer-aided drug discovery.
You may like
Recommended supplier
| Product name | Price | Suppliers | Update time | |
|---|---|---|---|---|
| $55.00/5mg |
VIP4Y
|
TargetMol Chemicals Inc.
|
2025-12-19 |
United States- Since: 2011-01-07
- Address: 36 Washington Street, Wellesley Hill, MA
INQUIRY